Liver cancer – HCC
Hepatocellular carcinoma
The global incidence of liver cancer is increasing, growing 3% per year in Asia and Europe, and around 1-2% in the United States
Identifying HCC patients at very early stage (stage 0) is a huge clinical unmet need
Current imaging diagnostics offer poor sensitivity for small lesions (1-2cm)
Median’s eyonis™ HCC
Unrivalled AI/ML Software as Medical Device (SaMD) enabling very early HCC diagnosis with unprecedented performance
The only end-to-end AI/ML tech-based CADe/CADx SaMD for very early stage HCC
Indicated for the detection, localization, and characterization of small nodules below 2cm
Unprecedented sensitivity and specificity versus standard of care
A radiological CADe device is “intended to identify, mark, highlight or otherwise direct attention to portions of an image that may reveal abnormalities during interpretation of images by the clinician”. A CADx device is “intended to provide information beyond identifying abnormalities, such as an assessment of disease”. Source: FDA
Additional indications
Lung cancer
Lung cancer screening (LCS) & incidental pulmonary nodules (IPN)
Liver fibrosis
Liver fibrosis in non-alcoholic steatohepatitis (NASH)
Latest news
PRESS RELEASE
Median Technologies Announces Rebranding of iBiopsy®, Changes Name to eyonis™
Median Technologies unveils a new identity, including a new name, logo, tagline for its iBiopsy® AI/ML tech-based suite of software as medical devices (SaMD) and business unit, as part of an extensive rebranding initiative. iBiopsy® becomes eyonis™.
PRESS RELEASE
Median Technologies to speak at the Radiological Society of North America 2023 Annual Meeting, Nov. 26 – 30, Chicago, IL, USA
AI Theater Presentation: “Transforming Cancer Diagnosis through End-to-End AI-Powered SaMD”
PRESS RELEASE
First results of Median Technologies’ iBiopsy® HCC detection AI model developed on the PHELICAR Clinical Data Registry, to be presented at the ESMO Congress(Oct 20-24, 2023, Madrid, Spain)
